The shares of Dynavax Technologies Corporation (NASDAQ:DVAX) has been pegged with a rating of Buy by H.C. Wainwright in its latest research note that was published on October 18, 2019. The Healthcare company has also assigned a $13 price target. H.C. Wainwright wasn’t the only research firm that published a report of Dynavax Technologies Corporation, with other equities research analysts also giving their opinion on the stock. Cantor Fitzgerald advised investors in its research note published on July 11, 2019, to Overweight the DVAX stock while also putting a $20 price target. The stock had earned Overweight rating from Cantor Fitzgerald Markets when it published its report on February 27, 2019. That day the Cantor Fitzgerald set price target on the stock to $28. Cantor Fitzgerald was of a view that DVAX is Overweight in its latest report on March 08, 2018. JP Morgan thinks that DVAX is worth Neutral rating.
Amongst the analysts that rated the stock, 0 have recommended investors to sell it, 0 believe it has the potential for further growth, thus rating it as Hold while 3 advised investors to purchase the stock. The consensus currently stands at a Buy while its average price target is $16.00. The price of the stock the last time has raised by 44.44% from its 52-Week high price while it is -68.45% than its 52-Week low price. A look at the stock’s other technical shows that its 14-day RSI now stands at 27.78.
The shares of the company added by 14.54% during the trading session on Tuesday, reaching a low of $2.30 while ending the day at $2.60. During the trading session, a total of 2.22 million shares were traded which represents a -55.58% decline from the average session volume which is 1.43 million shares. DVAX had ended its last session trading at $2.27. Dynavax Technologies Corporation debt-to-equity ratio currently stands at 21.52, while its quick ratio hovers at 3.20 DVAX 52-week low price stands at $1.80 while its 52-week high price is $8.24.
The company in its last quarterly report recorded -$0.34 earnings per share which is below the predicted by most analysts. The Dynavax Technologies Corporation generated 39.88 million in revenue during the last quarter. In the second quarter last year, the firm recorded -$0.49 earnings per share. Compared to the same quarter last year, the firm’s revenue was down by -82.35%. Dynavax Technologies Corporation has the potential to record -1.04 EPS for the current fiscal year, according to equities analysts.
Investment analysts at Raymond James published a research note on February 24, 2020 where it informed investors and clients that Goldman Sachs BDC Inc. (NYSE:GSBD) is now rated as Mkt Perform. Even though the stock has been trading at $12.33/share, analysts expect it to down by -12.33% to reach $20.56/share. It started the day trading at $12.6324 and traded between $10.80 and $10.81 throughout the trading session.
A look at its technical shows that GSBD’s 50-day SMA is 20.25 while its 200-day SMA stands at 20.25. The stock has a high of $22.50 for the year while the low is $11.60. The stock, however, witnessed a rise in its short on 02/28/20. Compared to previous close which recorded 220053.89 shorted shares, the short percentage went higher by 68.87%, as 371,605 DVAX shares were shorted. At the moment, only 0.92% of Goldman Sachs BDC Inc. shares were sold short. The company’s P/E ratio currently sits at 12.05, while the P/B ratio is 0.65. The company’s average trading volume currently stands at 207.24K shares, which means that the short-interest ratio is just 1.79 days. Over the past seven days, the company moved, with its shift of -40.60%. Looking further, the stock has dropped -51.52% over the past 90 days while it lost -47.17% over the last six months.
Following these latest developments, around 0.23% of Goldman Sachs BDC Inc. stocks are owned by institutional investors and hedge funds.